Report: Merck works to bring Zilmax back to market
Amid a cloud of uncertainty since Merck pulled Zilmax off the market in August, a company spokesperson said this week that it has plans to resume sales of the beta-agonist after it completes an audit of how the product is used.
According to an article from Reuters, a Merck spokeswoman said she could not speculate on when the sales will resume, but she did indicate the company intends to resume sales. It is the first word from Merck indicating they intend to reinstate the product.
Merck is in the process of auditing Zilmax's use, and developing a process to rectify feedyards.